Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 200 mg - tablet, uncoated - excipient ingredients: calcium carbonate; mannitol; hyprolose; fumaric acid; iron oxide yellow; magnesium stearate - treatment of erectile dysfunction in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; calcium carbonate; fumaric acid; mannitol; hyprolose - treatment of erectile dysfunction in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; fumaric acid; calcium carbonate; hyprolose; iron oxide yellow - treatment of erectile dysfunction in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - nicorandil, quantity: 10 mg - tablet - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; mannitol; stearic acid - for the treatment of chronic stable angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - nicorandil, quantity: 20 mg - tablet - excipient ingredients: stearic acid; pregelatinised maize starch; mannitol; croscarmellose sodium - for the treatment of chronic stable angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - itraconazole, quantity: 50 mg - capsule - excipient ingredients: silicon dioxide; magnesium stearate; sodium starch glycollate type a; hypromellose phthalate; gelatin; brilliant blue fcf; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - superficial mycoses: lozanoc is indicated, if external treatment is not effective or not appropriate, for the treatment of the following fungal infections: dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and pityriasis versicolor. systemic mycoses: lozanoc is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis. consideration should be given to official guidance on the appropriate use of antimycotic agents, and to the discussion of the pharmacodynamic properties (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - itraconazole, quantity: 50 mg - capsule - excipient ingredients: sodium starch glycollate type a; titanium dioxide; brilliant blue fcf; hypromellose phthalate; silicon dioxide; magnesium stearate; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - superficial mycoses: lozanoc is indicated, if external treatment is not effective or not appropriate, for the treatment of the following fungal infections: dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and pityriasis versicolor. systemic mycoses: lozanoc is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis. consideration should be given to official guidance on the appropriate use of antimycotic agents, and to the discussion of the pharmacodynamic properties (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - macitentan, quantity: 10 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; polysorbate 80; povidone; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - opsumit, as monotherapy or in combination with approved pah treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of: ?idiopathic pulmonary arterial hypertension ?heritable pulmonary arterial hypertension ?pulmonary arterial hypertension associated with connective tissue disease ?pulmonary arterial hypertension associated with congenital heart disease with repaired shunts in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 70.225 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350 - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 140.45 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; titanium dioxide; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350 - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.